Recombinant Allergens for the Diagnosis and Treatment of House Dust Mite Allergy

  • Martin D. Chapman
  • L. Karla Arruda
Part of the Allergy Frontiers book series (ALLERGY, volume 4)

Allergen-specific immunotherapy has been extensively used to treat patients with allergic diseases. Controlled studies provided evidence of the efficacy of immunotherapy as part of the treatment of patients with asthma, allergic rhinitis and those with severe reactions to hymenoptera venoms. In this chapter, we will review the current perspectives for using recombinant mite allergens for immunotherapy to treat patients with asthma and allergic rhinitis.


Allergic Rhinitis Allergy Clin Immunol Pollen Season Mite Allergen Positive Skin Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120(3 Suppl.):S25–85.CrossRefGoogle Scholar
  2. 2.
    Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma (Cochrane review). In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.Google Scholar
  3. 3.
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immuno therapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; 1:CD001936.Google Scholar
  4. 4.
    Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immuno-therapy. Nat Rev Immunol. 2006; 6:761–771.PubMedCrossRefGoogle Scholar
  5. 5.
    Chapman MD, Smith AM, Vailes LD, Arruda LK, Dhanaraj V, Pomés A. Recombinant allergens for diagnosis and therapy of allergic disease. J Allergy Clin Immunol 2000; 106:409–418.PubMedCrossRefGoogle Scholar
  6. 6.
    Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007; 119:826–830.PubMedCrossRefGoogle Scholar
  7. 7.
    Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, Kraft D, Valenta R. Component-resolved diagnosis of house-dust mite allergy with purified natural and recom-binant mite allergens. Clin Exp Allergy 2004; 34:597–603.PubMedCrossRefGoogle Scholar
  8. 8.
    Satinover SM, Reefer AJ, Pomes A, Chapman MD, Platts-Mills TAE, Woodfolk JA. Specific IgE and IgG antibody-binding patterns to recombinant cockroach allergens. J Allergy Clin Immunol 2005; 115:803–809.PubMedCrossRefGoogle Scholar
  9. 9.
    King EM, Vailes LD, Tsay A, Satinover SM, Chapman MD. Simultaneous detection of total and allergen-specific IgE by using purified allergens in a fluorescent multiplex array. J Allergy Clin Immunol 2007; 120:1126–1131.PubMedCrossRefGoogle Scholar
  10. 10.
    Hiller R, Laffer S, Harwanegg C, Huber M, Schmid W, Twardosz A, Becker WM, Blaser K, Brelteneder H, Chapman MD, Crameri R, Duchene M, Ferreira F, Fiebig H, Hoffmann-Sommergruber K, King TP, Kleber-Janke T, Kurup VP, Lehrer SB, Lidholm J, Müller U, Pini C, Reese G, Scheiner O, Scheynius A, Shen H, Spitzauer S, Suck R, Swoboda I, Thomas W, Tinghino R, van Hage-Hamsten M, Virtanen T, Kraft D, Müller MW, Valenta R. Microarrayed allergen molecules: Diagnostic gatekeepers for refined allergy treatment. FASEB J 2002; 16:414–416.PubMedGoogle Scholar
  11. 11.
    Cromwell O, Fiebig H, Suck R, Kahlert H, Nandy A, Kettner J, Narkus A. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin N Am 2006; 26:261–281, vii.CrossRefGoogle Scholar
  12. 12.
    Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M-T, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Nat Acad Sci USA 2004; 101(Suppl. 2):14677–14682.PubMedCrossRefGoogle Scholar
  13. 13.
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608–613.PubMedCrossRefGoogle Scholar
  14. 14.
    Platts-Mills TA. The role of indoor allergens in chronic allergic disease. J Allergy Clin Immunol 2007; 119:297–302.PubMedCrossRefGoogle Scholar
  15. 15.
    Erwin EA, Rönmark E, Wickens K, Perzanowski MS, Barry D, Lundbäck B, Crane J, Platts-Mills TA. Contribution of dust mite and cat specific IgE to total IgE: relevance to asthma prevalence. J Allergy Clin Immunol 2007; 119:359–365.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobi-ology of house dust mite allergens. Int Arch Allergy Immunol 2002; 129:1–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Trombone AP, Tobias KR, Ferriani VP, Schuurman J, Aalberse RC, Smith AM, Chapman MD, Arruda LK. Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. Clin Exp Allergy 2002; 32:1323–1328.PubMedCrossRefGoogle Scholar
  18. 18.
    Santos AB, Chapman MD, Aalberse RC, Vailes LD, Ferriani VP, Oliver C, Rizzo MC, Naspitz CK, Arruda LK. Cockroach allergens and asthma in Brazil: identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens. J Allergy Clin Immunol 1999; 104:329–337.PubMedCrossRefGoogle Scholar
  19. 19.
    Fernández-Caldas E, Iraola V, Boquete M, Nieto A, Casanovas M. Mite immunotherapy. Curr Allergy Asthma Rep 2006; 6:413–419.PubMedCrossRefGoogle Scholar
  20. 20.
    Cohon A, Arruda LK, Martins MA, Guilherme L, Kalil J. Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J Allergy Clin Immunol 2007; 120:210–213.PubMedCrossRefGoogle Scholar
  21. 21.
    Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immuno-therapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021–1035.PubMedCrossRefGoogle Scholar
  22. 22.
    Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162–1172.PubMedCrossRefGoogle Scholar
  23. 23.
    Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, Bahceciler NN, Barlan IB. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmaco-therapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007; 18: 508–515.PubMedCrossRefGoogle Scholar
  24. 24.
    Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW, Passalacqua G. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164–170.PubMedCrossRefGoogle Scholar
  25. 25.
    Schmid-Grendelmeier P, Crameri R. Recombinant allergens for skin testing. Int Arch Allergy Immunol 2001; 125:96–111.PubMedCrossRefGoogle Scholar
  26. 26.
    Genov IR, Jorge PPO, Trombone APF, Tobias KRC, Ferriani VPL, Smith AM, Chapman MD, Arruda LK. Use of cocktails of recombinant allergens for diagnosis of mite allergy in patients with asthma and/or rhinitis. J Allergy Clin Immunol 2002; 109:S163 [Abstract].CrossRefGoogle Scholar
  27. 27.
    Lynch NR, Puccio FS, Di Prisco MC, Escudero JE, Nozzolino M, Hazel LA, Smith WA, Thomas WR. Association between allergic disease and reactivity to recombinant Der p 2 allergen of house dust mites in a tropical situation. J Allergy Clin Immunol 1998; 101:562–564.PubMedCrossRefGoogle Scholar
  28. 28.
    Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J Allergy Clin Immunol 1998; 101:423–425.PubMedCrossRefGoogle Scholar
  29. 29.
    Kronqvist M, Johansson E, Whitley P, Olsson S, Gafvelin G, Scheynius A, van Hage-Hamsten M. A hypoallergenic derivative of the major allergen of the dust mite Lepidoglyphus destructor, Lep d 2.6Cys, induces less IgE reactivity and cellular response in the skin than recombinant Lep d 2. Int Arch Allergy Immunol 2001; 126:41–49.PubMedCrossRefGoogle Scholar
  30. 30.
    Yi FC, Chua K Y, Cheong N, Shek LP, Lee BW. Immunoglobulin E reactivity of native Blo t 5, a major allergen of Blomia tropicalis. Clin Exp Allergy 2004; 34:1762–1767.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsai JJ, Yi FC, Chua K Y, Liu YH, Lee BW, Cheong N. Identification of the major allergenic components in Blomia tropicalis and the relevance of the specific IgE in asthmatic patients. Ann Allergy Asthma Immunol 2003; 91:485–489.PubMedCrossRefGoogle Scholar
  32. 32.
    Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:777–783.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Martin D. Chapman
    • 1
  • L. Karla Arruda
    • 2
  1. 1.Indoor Biotechnologies, Inc.CharlottesvilleUSA
  2. 2.Department of MedicineSchool of Medicine of Ribeirão Preto — University of São PauloRibeirão PretoBrazil

Personalised recommendations